Is Valeant on track to overcome financial troubles? Mizuho’s Irina Rivkind Koffler remains unconvinced.
David Maris: Valeant is getting rid of an opportunity that would never translate to money.
Irina Rivkind Koffler warns VRX will face the brunt of various large scope headwinds.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced today that it will pay down $125 million of senior secured loans, keeping it on track with …
Healthcare analysts take different approaches to valuing Transenterix and Valeant.
Fears about financial control should be a buying opportunity in Valeant stock, says Cantor.
Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) Ortho Dermatologics division announced results from the Pivotal Phase 3 long-term extension study (AMAGINE-2), which demonstrated that SILIQ™ (brodalumab) …
TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.
Valeant’s comeback progresses with new notes offering; RedHill ups the risk ante in favor of time/money.
Bausch + Lomb, a division of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced the introduction of Biotrue® ONEday for Astigmatism daily disposable contact lenses in 20 …
